Sio Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Sio Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$505K	Hold	40,000	–	–	0.07%	65
2025 Q4	$631K	Buy	+40,000	New	+$508K	0.1%	61
2025 Q3	–	Sell	-178,774	Closed	-$1.35M	–	58
2025 Q2	$1.35M	Buy	178,774 +1,770	+1%	+$10.6K	0.52%	36
2025 Q1	$977K	Hold	177,004	–	–	0.29%	41
2024 Q4	$1.02M	Hold	177,004	–	–	0.29%	37
2024 Q3	$1.83M	Hold	177,004	–	–	0.73%	24
2024 Q2	$2.3M	Hold	177,004	–	–	0.62%	28
2024 Q1	$3.09M	Buy	+177,004	New	+$2.34M	0.92%	31

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Sio Capital Management's ENTA Position: Q1 2026 in Review

Sio Capital Management held its Enanta Pharmaceuticals (ENTA) position steady in Q1 2026 at 40,000 shares worth $505K. The position accounts for 0.07% of the portfolio, ranked #65.

Sio Capital Management first reported a position in ENTA in Q1 2024 and has held it in 8 quarters since. The position peaked at $3.09M in Q1 2024. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

Sio Capital Management held 40,000 shares of Enanta Pharmaceuticals worth $505K as of Q1 2026.
Sio Capital Management left its Enanta Pharmaceuticals share count unchanged in Q1 2026.
Enanta Pharmaceuticals made up 0.07% of Sio Capital Management's portfolio in Q1 2026, its #65 holding.
Sio Capital Management first reported a position in Enanta Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
Sio Capital Management's Enanta Pharmaceuticals position peaked at $3.09M in Q1 2024.
132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Sio Capital Management's 13F filing for Q1 2026, filed 14 May 2026.